TELO
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$1.16
+0.00%Next report
Analyst consensus
- Next report date
- Dec 2, 2026
- EPS estimate
- -$0.08
- Revenue estimate
- $500.0K
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.79
- EPS estimate
- -$0.07
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -264.7%
- Revenue beats (12Q)
- —
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Dec 2, 2026